Saltar al contenido
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文（繁體）
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Lenguaje
Todos los Campos
Título
Autor
Materia
Número de Clasificación
ISBN/ISSN
Etiqueta
Buscar
Avanzado
Rationale, design and patients...
Citar
Describir
Enviar este por Correo electrónico
Imprimir
Exportar Registro
Exportar a RefWorks
Exportar a EndNoteWeb
Exportar a EndNote
Enlace Permanente
Rationale, design and patients' baseline characteristics of the PERFORM study
Detalles Bibliográficos
Autores principales:
Bousser, MG
,
Amarenco, P
,
Chamorro, A
,
Fisher, M
,
Ford, I
,
Fox, K
,
Rothwell, P
,
Hennerici, MG
,
Mattle, H
,
Kim, J
Formato:
Conference item
Publicado:
2009
Existencias
Descripción
Ejemplares similares
Vista Equipo
Ejemplares similares
Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study.
por: Bousser, MG, et al.
Publicado: (2009)
The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population.
por: Bousser, MG, et al.
Publicado: (2009)
Heart rate is a prognostic risk factor for myocardial infarction: a post hoc analysis in the PERFORM (Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack) study population.
por: Fox, K, et al.
Publicado: (2013)
Heart rate is a prognostic risk factor for myocardial infarction: A post hoc analysis in the PERFORM (Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history of ischemic strOke or tRansient ischeMic attack) study population
por: Fox, K, et al.
Publicado: (2013)
Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial.
por: Bousser, MG, et al.
Publicado: (2011)